2Xideas AG Sells 21,484 Shares of Lantheus Holdings, Inc. $LNTH

2Xideas AG decreased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 30.4% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 49,079 shares of the medical equipment provider’s stock after selling 21,484 shares during the period. 2Xideas AG’s holdings in Lantheus were worth $4,018,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the business. Nuveen LLC bought a new stake in Lantheus during the 1st quarter worth about $55,941,000. Norges Bank acquired a new stake in shares of Lantheus in the second quarter valued at about $32,631,000. Epoch Investment Partners Inc. bought a new stake in Lantheus during the first quarter worth about $35,548,000. Nitorum Capital L.P. bought a new stake in Lantheus during the first quarter worth about $23,261,000. Finally, Reinhart Partners LLC. boosted its position in Lantheus by 16.4% during the second quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock valued at $114,905,000 after purchasing an additional 197,719 shares during the last quarter. Institutional investors own 99.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on LNTH. Truist Financial reaffirmed a “hold” rating and set a $61.00 price target (down previously from $63.00) on shares of Lantheus in a research report on Monday, November 10th. The Goldman Sachs Group set a $77.00 target price on shares of Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th. Weiss Ratings lowered shares of Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. TD Cowen cut their price target on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, September 15th. Finally, B. Riley lowered their price objective on shares of Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, September 16th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $74.17.

Lantheus Stock Down 1.6%

LNTH opened at $62.27 on Tuesday. The stock’s fifty day simple moving average is $55.73 and its 200 day simple moving average is $63.34. Lantheus Holdings, Inc. has a 1-year low of $47.25 and a 1-year high of $111.29. The stock has a market cap of $4.13 billion, a PE ratio of 26.16 and a beta of -0.10. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. The firm had revenue of $92.51 million for the quarter. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. As a group, research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.